BElikelihood
Likelihood Method for Evaluating Bioequivalence
A likelihood method is implemented to present evidence for evaluating bioequivalence (BE). The functions use bioequivalence data [area under the blood concentration-time curve (AUC) and peak concentration (Cmax)] from various crossover designs commonly used in BE studies including a fully replicated, a partially replicated design, and a conventional 2x2 crossover design. They will calculate the profile likelihoods for the mean difference, total standard deviation ratio, and within subject standard deviation ratio for a test and a reference drug. A plot of a standardized profile likelihood can be generated along with the maximum likelihood estimate and likelihood intervals, which present evidence for bioequivalence. See Liping Du and Leena Choi (2015)
- Version1.1
- R version≥ 3.5.0
- LicenseGPL (≥ 3)
- Needs compilation?No
- Last release03/05/2024
Documentation
Team
Liping Du
Leena Choi
Cole Beck
Insights
Last 30 days
Last 365 days
The following line graph shows the downloads per day. You can hover over the graph to see the exact number of downloads per day.
Data provided by cranlogs
Binaries
Dependencies
- Depends1 package
- Imports2 packages
- Suggests3 packages